Purposes: Despite recommendations against prostate cancer screening with prostate-specific antigen (PSA) tests, about one-fourth of men age >40 years received PSA tests in 2015. This study aimed to answer 3 questions for men who had a PSA test in the past year: (1) What percentage of these men received the test first suggested by physicians? (2) What factors were associated with physician-initiated PSA testing (PIPT) versus patient/someone else-initiated testing? (3) What percentage of patients ever had shared decision-making when tests were initiated by physicians?
Results
The age-standardized prevalence of PIPT was significantly higher in 2015 (84.9%) than in 2000 (72.3%) (P Ͻ .01). In 2015, among men aged Ն70 years who received a PSA screening test, nearly 90% reported that it was first suggested by a physician (Table 1) . PIPT was positively associated with 2 or more comorbid conditions and number of patient visits to the doctor, but inversely associated with prostate cancer family history (data not shown). Up to one-third of men who were screened reported that they had ever participated in a discussion of advantages and disadvantages of PSA testing (Table 2) ; SDM was slightly higher with PIPT (32% vs 25% for initiation by the patient/ someone else), but not significantly so (P ϭ .06).
Discussion
In 2000 and 2015, more than 70% of men who underwent PSA testing in the past year reported that their physicians were the first to suggest testing. Conflicting recommendations regarding PSA testing might have contributed to that high prevalence. 1 Other factors might include physician beliefs about PSA screening effectiveness, perceived community standard of care, and malpractice concerns. 2 Medicare reimbursement for annual PSA testing might contribute to the willingness of physicians to propose or support testing.
PIPT is positively associated with 2 or more comorbid conditions and the number of patient encounters with clinicians. More patient encounters may increase a clinician's opportunity to suggest the test. This study suggests that men with prostate cancer family history are more likely to first suggest PSA testing. In 2017, the US Preventive Task Force released draft recommendations, instead of against screening among men of all ages, calling for individualized decision making after discussion of potential benefits and harms of PSA testing among men aged 55 years to 69 years. 3 In our study, more than two-thirds of men who were screened reported that they had never discussed advantages and disadvantages of PSA testing with physicians, a finding consistent with previous reports. 4, 5 These results point to the challenges and needs in conducting SDM in clinical practice.
Limitations of our study include self-reported data (which may be less accurate than medical records), results that may not be representative of nonrespondents, and lack of details on the relationship to the patient when "someone else requested the test." PSA, prostate-specific antigen testing; CI, confidential interval. *Status of "Ever discussed advantages and disadvantages" was assessed based on two survey questions: (1) Did a doctor ever talk with you about the advantages of the test?; and (2) Did a doctor ever talk with you about the disadvantages of the test. † Number may differ from the total of 2024 because of "don't know," refused, or missing responses.
